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Abstract
Urinary tract infection due to uropathogenic E. coli is a common clinical problem. The 
innate immune system and the uroepithelium are critical in defence against infection. The 
complement system is both part of the innate immune system and influences the 
interaction between epithelium and pathogen. We have therefore investigated the 
mechanism by which uropathogenic E. coli activate complement and the potential for this 
to occur during clinical infection. The classical pathway is responsible for bacterial 
opsonisation when complement proteins are present at low concentrations. At higher 
concentrations the alternative pathway predominates but still requires the classical 
pathway for its initiation. In contrast the mannose binding lectin pathway is not involved. 
Early classical pathway components are present in the urine during infection and actively 
contribute to bacterial opsonisation. The classical pathway could be initiated by anti- E.
coli antibodies of IgG or IgM subclasses that are present in urine during infection. 
Additionally immunoglobulin-independent mechanisms, such as direct C1q binding to 
bacteria, may be involved. In conclusion uropathogenic E. coli are readily opsonised by 
complement in a classical pathway dependent manner. This can occur within the urinary 
tract during the development of clinical infection.
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2Abstract
Urinary tract infection due to uropathogenic E. coli is a common clinical problem. 
The innate immune system and the uroepithelium are critical in defence against 
infection. The complement system is both part of the innate immune system and 
influences the interaction between epithelium and pathogen. We have therefore 
investigated the mechanism by which uropathogenic E. coli activate complement and 
the potential for this to occur during clinical infection. The classical pathway is 
responsible for bacterial opsonisation when complement proteins are present at low 
concentrations. At higher concentrations the alternative pathway predominates but 
still requires the classical pathway for its initiation. In contrast the mannose binding 
lectin pathway is not involved. Early classical pathway components are present in the 
urine during infection and actively contribute to bacterial opsonisation. The classical 
pathway could be initiated by anti- E. coli antibodies of IgG or IgM subclasses that 
are present in urine during infection. Additionally immunoglobulin-independent 
mechanisms, such as direct C1q binding to bacteria, may be involved. In conclusion 
uropathogenic E. coli are readily opsonised by complement in a classical pathway 
dependent manner. This can occur within the urinary tract during the development of 
clinical infection.
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3Introduction
Bacterial infection of the urinary tract is a common clinical problem, estimated to 
affect 40-50% of women at least once in their life time (Foxman et al., 2000).
Frequent recurrence is an important characteristic of these infections, as up to 25% of 
women who experience a first urinary tract infection (UTI) will have a second 
infection within 6 months (Foxman, 1990). Recent research indicates that E. coli can 
establish long-lived intracellular reservoirs within the bladder mucosa of mice without 
bacteriuria (Mulvey et al., 2001; Mysorekar and Hultgren, 2006; Schilling et al., 
2002). These persistent intracellular reservoirs may explain the recurrent nature of 
UTI in humans. Protection against microbial infection is usually achieved by the 
cooperation between adaptive and innate immune defences. However, adaptive 
immunity does not play an important role in the early clearance of bacteria from the 
urinary tract, as immunodeficient mice lacking B or T lymphocytes do not show an 
enhanced UTI susceptibility (Jones-Carson et al., 1999). Therefore, understanding the 
interactions between E. coli and the host’s innate immune response is critical in 
understanding the pathogenesis of this important infection.
An important component of innate immunity against many microorganisms is the 
complement system. Bacterial and viral pathogens can active the complement system 
via three distinct pathways: the classical, mannose binding lectin (MBL) and 
alternative pathways. The classical pathway is initiated by the binding of C1q either 
directly to bacteria (Alberti et al., 1993; Butko et al., 1999; Clas and Loos, 1981), 
indirectly via the Fc-portion of antibody (IgG or IgM) -antigen complexes on the 
bacterial surface or to the acute-phase reactant C reactive protein (CRP) bound to 
phosphorylcholine on the bacterial surface (Mold et al., 2002; Yother et al., 1982). 
The alternative and MBL pathways are activated by direct binding of complement 
4proteins to bacterial cell surface components (Walport, 2001). The activation of C3 is 
the convergence point of the three pathways of complement activation. C3 is cleaved 
into C3a and C3b, exposing an internal thiolester bond allowing the C3b to bind
covalently to hydroxyl groups (carbohydrates) or amine groups (proteins) on the 
pathogen surface. C3b tags a pathogen as foreign and the bound C3 acts as a focus for 
further complement activation on and around the microbe. 
Complement activation protects against infection in several ways. Firstly, 
complement activation leads to opsonisation of pathogens, thereby enhancing 
phagocytosis by macrophages and neutrophils. Secondly, activation releases the small 
complement cleavage fragments C3a and C5a, which act as chemoattractants to 
recruit more phagocytes to the site of infection and also active these phagocytes. 
Thirdly, formation of the membrane attack complex (C5b-9) on the surface of certain
pathogens can result in their direct lysis. Finally, the complement system has an 
important role in augmenting the adaptive immune response (Carroll, 2004; Dempsey 
et al., 1996).
Several observations suggest that complement plays an important role in the 
pathogenesis of ascending UTI. First, production of complement proteins within the 
kidney is increased in response to cytokines associated with acute infection
(Brooimans et al., 1991; Seelen et al., 1993). Second, most uropathogens are resistant 
to killing by complement suggesting evolutionary pressure on bacteria to develop 
resistance. Third, previous studies have shown that decomplementation by cobra 
venom factor (CVF) decreases the degree of tissue damage during renal infection
(Glauser et al., 1978; Roberts et al., 1983; Shimamura, 1981). Furthermore, studies 
from our group have shown that mice deficient in C3 are resistant to ascending 
infection and complement can alter bacterial uptake by mouse uroepithelial cells
5(Springall et al., 2001). Recently we reported that the C3 concentration in the urine of 
patients rises sufficiently during infection to allow bacterial opsonisation and that
opsonised E. coli invade human uroepithelial cells via CD46, a complement 
regulatory protein expressed on host cell membranes (Li et al., 2006). 
In the present study, we defined the mechanism by which C3 opsonises uropathogenic 
E. coli in human serum and infected urine. We evaluated the role of each complement 
pathway, the source of urinary complement proteins and assessed how complement 
activation is initiated.
6Materials and methods
Bacterial strains
The uropathgenic E. coli strain J96 (serotype O4: K6) was provided by Dr. R. Welch, 
(University of Wisconsin, Madison, USA). It is a serum resistant, haemolysin 
secreting E. coli strain that expresses both Type 1 and P fimbriae (O'Hanley et al., 
1985). GR12 (O75: K5), a non-haemolytic human pyelonephritis isolate was provided 
by Dr. R. Hull (Baylor College of Medicine, Texas, USA) (Svanborg Eden et al., 
1983). Bacteria were grown in 5 ml of static Luria-Bertani (LB) broth at 37
o
C for 16 
hours to induce fimbrial expression prior to use in experiments. For each experiment 
bacterial concentration was standardised by photospectrometry at 600nm, and colony 
number confirmed using serial dilutions and plating to agar plates.
Sera, complement proteins and buffers 
Normal human serum (NHS) was obtained from 5 healthy volunteers. After 
collection, samples were pooled and stored at -70
o
C for up to 3 months. C1q depleted 
serum and purified C1q were purchased from Quidel (San Diego, USA). MBL 
deficient and sufficient sera were purchased from Antibody Shop (Gentofte,
Denmark). Complement activation was assessed in isotonic VBS. In GVBS
++
 buffer 
(VBS with 0.1% gelatin, 0.15mM CaCl2, and 1.0mM MgCl2), all complement 
pathways are active. In Mg-EGTA-GVBS buffer (VBS with 5mM MgCl2 and 8mM 
EGTA, pH 7.5) only the alternative complement pathway is active. EDTA-GVBS
--
buffer (GVBS with 10mM EDTA) inhibits all complement pathways. High ionic 
strength buffer (GVBS
++
 buffer containing 1M NaCl) inhibits the binding of C1q to 
immune complexes and disrupts the C1 complex (Burton et al., 1980), whereas the 
MBL pathway is unaffected. In contrast, buffer containing mannose (GVBS
++
 buffer 
with 100nM mannose) inhibits the MBL pathway specifically (Petersen et al., 2000).
7Urine samples
Urine samples were collected from patients with E. coli acute lower urinary tract 
infection (20 samples, provided by the Department of Microbiology, Guy’s and St 
Thomas’ National Health Service Foundation Trust) and healthy volunteer controls (6 
samples). Each urine sample was spun at 2000 rpm for 15 minutes at 4
o
C and passed 
through a 0.2 ?m filter to remove cell debris and bacteria. Samples were aliquoted 
and immediately stored at -70
 o
C for future analysis.
C3 and C4 deposition on E. coli
E. coli (2×108 c.f.u) were washed and incubated in VBS buffers containing NHS at 
37
o
C. In the initial experiments, E. coli were incubated in different serum 
concentrations in different complement activation buffers for the times specified.  At 
the end of the incubation period, the bacteria were washed in EDTA-GVBS
--
 to stop 
further complement activation. E. coli were then stained with rabbit anti-human C3 
(1:100 dilution) (Serotec, Oxfordshire, UK) or mouse anti-human C4d (10µg/ml, 
Quidel) for 1 hour at 25
o
C. Bacteria were washed again then stained with FITC-
labelled swine anti-rabbit IgG (1:100 dilution, Serotec) or goat anti-mouse IgG 
(1:100, Sigma-Aldrich, Dorset, UK). After washing, bacteria were fixed with 1% 
paraformaldehyde and analysed by flow cytometry. The intensity of staining was 
analysed using CellQuest software (BD Biosciences, Cowley, UK). 
In some experiments, E. coli J96 were added to urine with either EGTA (8mM EGTA 
with 5mM MgCl2) or EDTA (10mM) and incubated at 37
 o
C for 2 hours.  Urine had 
been concentrated 10 fold by centrifugation (Vivaspin (molecular weight cut off 
5kDa), Sartorius AG, Goettingen, Germany). At the end of incubation period, 
bacterial-bound complement proteins were eluted with 4mM sodium carbonate, 
46mM sodium bicarbonate (pH 9.2) for 2 hours at 37
o
C (de Astorza et al., 2004). 
8Bacteria were removed by centrifugation. Eluted proteins were separated by 10% 
SDS-PAGE under reducing conditions and transferred to a Hybond–c Extra 
membrane (GE Healthcare UK Limited, Bucks, UK). The membrane was sequentially 
incubated with blocking buffer (phosphate buffered saline (PBS)-5% milk powder) at 
4
o
C overnight, rabbit anti-human C3c (1/1000; Dako UK Ltd, Cambridgeshire, UK), 
and peroxidase-conjugated goat anti-rabbit IgG (1/5000; Dako). The membrane was 
then developed using the ECL system (GE Healthcare UK Limited).
Initiation of complement activation
Binding of human Ig (IgG, IgM & IgA), CRP, C1q and MBL to E. coli surface was 
assessed by FACS staining. E. coli were incubated in 5% serum for 30 minutes or 
incubated with infected urine for 2 hours, followed by staining with specific Abs 
(mouse anti-human Igs and rabbit anti-human CRP are from Sigma-Aldrich, rabbit 
anti-human C1q from Dako, mouse anti-MBL from Antibody Shop) followed by a 
FITC-labelled secondary Ab. Monoclonal Abs were used at 10µg/ml and polyclonal 
Abs at a dilution of 1:100. To demonstrate that C1q and CRP can directly bind to E.
coli, purified C1q (25µg/ml, Quidel) or purified CRP (160ng/ml and 1600ng/ml, 
Cambridge Bioscience Ltd, Cambridge, UK) were incubated with 2×10
8
c.f.u J96 for 
30 minutes followed by staining as above.
Detection of urinary complement proteins
Urine samples were eletrophoresed on 10% (C4, and C2) or 15% (C1q) SDS-PAGE 
gels under reducing conditions and transferred to a Hybond-c Extra membrane. 
Membranes were sequentially incubated with blocking buffer at 4
o
C overnight and 
then incubated with anti-C1q, C4, and C2 polyclonal Abs (1/1000, rabbit anti-human 
C1q from Dako, rabbit anti-human C4 from Serotec, goat anti-human C2 from 
Quidel), followed by peroxidase-conjugated secondary Abs (1/5000, Dako). 
9Membranes were developed using the ECL system. In addition, C1q concentration 
was measured by ELISA. In brief, 96 well plates (Nunc, Roskilde, Denmark) were 
coated overnight at 4
o
C with mouse anti-human C1q (Quidel) diluted 1/200 in PBS. 
After blocking with PBS containing 1% bovine serum albumin (BSA), the plate was 
incubated with appropriately diluted urine samples, followed by rabbit anti-human 
C1q (Dako) diluted 1/3000, then peroxidase conjugated goat anti-rabbit IgG (Dako) 
diluted 1/5000. Each antibody incubation was performed in 100µl PBS containing 1% 
BSA, 0.1% Tween 20 at 37
o
C for 1 hour and followed by washing in PBS containing 
0.1% Tween 20. The enzyme activity was assessed after incubation with O-
phenylenediamine by measuring absorbance at 490nm. Purified C1q (1.0mg/ml, 
Quidel) was used to generate a standard curve. The limit of sensitivity of this assay 
was 0.25ng/ml. ELISA studies were performed in triplicate. Urinary creatinine, 
albumin and CRP levels were measured by standard methodology.
Statistical analysis
Data analysis was performed using the statistical analysis option in the Prism graph 
pad program. P values were determined by using the unpaired two-tailed Student t test 
on logarithmically transformed data. 
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Results
We have shown previously that C3 deposition on uropathogenic E. coli was 
detectable after incubation in serum concentrations as low as 1%, and was maximal in 
serum concentrations above 10% (Li et al., 2006). To define which complement 
activation pathway has the major role in opsonisation of E. coli, we further assessed 
the relative contribution of each complement activation pathway.
The contribution of the alternative pathway to C3 opsonisation
Mg-EGTA buffer was used to dissect whether the alternative pathway or
classical/MBL pathways were responsible for bacterial opsonisation. Mg-EGTA 
buffer disrupts the Ca
++
-dependent C1 and MBL-MASP complexes and blocks the 
ligand binding of MBL, therefore inhibiting activation of the classical and MBL 
pathways. In this buffer the alternative pathway alone contributes to C3 opsonisation 
of E. coli. At a higher complement protein concentration (above 10% NHS) the 
alternative pathway predominated, accounting for 90% of total C3 deposition on J96 
(Fig.1A and C). In contrast at lower protein concentrations, (from 1% to 5% NHS) the 
classical/MBL pathways were predominately responsible for C3 opsonisation (Fig.1A 
and B). To investigate whether this mechanism of C3 opsonisation was exclusive to 
E. coli J96 or was also seen in other pyelonephritic strains, C3 opsonisation of a 
second pyelonephritic strain, GR-12, was assessed. This strain also activated 
complement through the classical/MBL pathways in lower serum concentrations 
(Fig.1D). Therefore the relative contribution of each pathway is dependent on 
complement protein concentration with the activity of the alternative pathway limited 
to higher concentrations.
Kinetics of C3 deposition by the alternative pathway
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Although, at higher complement protein concentrations, the alternative pathway is 
responsible for most of the C3 deposited on the surface of bacteria the classical/MBL 
pathways may be involved in initiating complement activation. We examined C3 
deposition over time at different serum concentrations. As shown in Fig.2 (A and B), 
C3 deposition on E. coli was rapid when all complement pathways were active 
(maximal at 5 minutes), in either lower (2%) or higher (10%) serum concentrations. 
C3 deposition by the alternative pathway alone was only observed at a higher serum 
concentration (10%) and even then maximal C3 deposition was achieved only after 30 
minutes (Fig. 2B). Similar results were seen with serum concentrations up to 50% 
(data not shown). Therefore, the classical and/or MBL pathways are important in the 
initiation of complement activation at higher concentrations of complement proteins. 
In contrast, the alternative pathway is important in amplification to obtain maximal 
bacterial opsonisation.
Classical and MBL pathway opsonisation of E. coli
At low complement protein concentration (up to 5% NHS) pathways other than the 
alternative pathway were mainly responsible for complement activation. We further 
dissected the relative contribution of the classical and MBL pathways. To exclude an 
effect of the alternative pathway we measured C4 deposition on the surface of E. coli 
as a marker of complement activation. To study the contribution by the MBL 
pathway, the classical pathway was specifically inhibited by using either C1q depleted 
serum or normal serum diluted in high ionic strength buffer (buffer containing 1M 
NaCl) (Burton et al., 1980). C4 deposition did not occur in the either 5% C1q depleted 
serum or normal serum diluted in high ionic strength buffer (Fig. 3A and B). 
suggesting that the MBL pathway contributed little to complement opsonisation of E.
coli. To confirm this, C4 deposition was assessed after incubation of E coli in MBL 
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deficient serum or normal serum diluted in mannose-containing buffer (100mM 
mannose). As predicted, C4 deposition was not reduced by absence or inhibition of 
MBL activity (Fig 3C and D). This confirms that the classical pathway plays a critical 
role in complement activation and bacterial opsonisation at lower complement protein 
concentrations.
E. coli activates the classical pathway and fixes C3 protein in infected urine
Our previous study demonstrated that during infection the concentrations of C3 in the 
urine were significantly increased (healthy controls C3: 0.5-92ng/ml, patients with 
infection C3: 12-14,400ng/ml) and C3 could opsonise bacteria incubated in infected 
urine (Li et al., 2006). C3 opsonisation of bacteria in urine is reduced in the presence 
of Mg-EGTA, providing direct evidence that C3 binding is due mainly to complement 
activation via the classical pathway (Fig. 4). 
Next, we assessed whether other classical pathway components are present in the 
urine. The early components of the classical pathway (C1q, C4 and C2) were detected 
in the urine of infected patients (Fig. 5). They were not detectable in the urine of 
healthy volunteers. To confirm the increase concentration of complement protein in 
the urine during infection, the C1q concentration was measured by ELISA. Up to 
3.5µg/ml of C1q (equivalent to approximately 4.4% of the normal serum 
concentration) was detected in the urine of patients with UTI. Because all the samples 
are single spot urine samples the level of C1q detected may not reflect the total 
amount of C1q in urine due to differences in urine flow rate. Therefore, urine 
creatinine concentration was used to correct for urine volume variation (Fig. 6). There 
was a significant increase (approximately 150 fold) in the C1q/Cr ratio during 
infection (median 6.8 and 976mg/mmol in control and infected urine respectively, 
P<0.01, Fig 6A). These complement components could be derived from local 
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synthesis within the urinary tract or from leakage of plasma proteins into the urine 
across inflamed epithelial surfaces. After correcting the C1q concentration for urinary 
albumin concentration an increase in C1q/albumin ratio was evident during infection 
(C1q/Albumin ratio median 1.52 and 20.57ng/mg in control and infected urine, 
P<0.02, Fig 6B). This suggests that, during infection, local synthesis contributes to the 
increase in C1q concentration in the urine.
Initiation of complement activation on E. coli
Classical pathway activation is predominantly initiated by C1q binding to the Fc 
portion of immune complexes (containing IgM and IgG) on the bacterial surface
(Walport, 2001). To determine whether immunoglobulins in serum and infected urine 
could bind to E. coli, we incubated J96 in NHS or urine and then assessed IgG, IgM 
and IgA binding by FACS. In both infected urine and serum from healthy volunteers, 
IgG, IgM and, at a lower level, IgA antibodies are present that bind to E. coli J96 and 
therefore could potentially contribute to complement activation. 
However, the classical pathway may also be activated by immunoglobulin-
independent mechanisms. C1q can bind directly to some pathogens or interact with 
other non-immunoglobulin proteins (e.g. CRP) which bind bacteria. The potential for 
these mechanisms to initiate complement activation on uropathogenic E. coli was 
therefore investigated. C1q was detected bound to the bacterial surface by FACS 30 
minutes after incubation with purified C1q (25?g/ml). In response to infection, CRP 
was detectable in the urine of concentrations up to 300ng/ml (n=6, 4-300ng/ml). This 
was significantly higher than seen in samples from healthy volunteers, in whom CRP 
was undetectable (n=4). The ability of CRP to bind to phosphocholine(PCh)–
containing bacteria (mostly Gram-positive) and activate human complement is well 
established. Whether CRP can bind to the Gram-negative pathogen E. coli is still 
14
unknown.  To investigate this, E. coli J96 were pre-incubated with purified human 
CRP for 30 minutes, then deposition of CRP on the bacterial surface detected by 
FACS staining using rabbit anti-human CRP. As shown in Fig. 8B CRP binding to E.
coli could be demonstrated at CRP concentrations equivalent to those seen in infected 
urine. Therefore, the initiation of classical complement pathway activation could be 
through immune complex dependent or independent mechanisms. 
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Discussion
Uropathogenic E. coli is the most common pathogen causing acute pyelonephritis, the 
severest form of UTI. However, within the urinary tract, the presence of bacteria 
alone is not sufficient to cause kidney infection as asymptomatic bacteruria has been 
shown to occur in up to 7% of adult women (Kunin and McCormack, 1968). Host 
factors, in particular the innate immune response, may influence whether bacterial 
exposure leads to infection. Complement is an important element in innate immune 
response and previous investigations have suggested C3 opsonisation can augment E.
coli internalisation into uroepithelial cells, an increasingly recognised feature of 
bacterial infection of the renal tract. In the current study, we described how 
complement is activated in response to infection with uropathogen E. coli.
During the development of renal tract infection, E. coli would encounter complement 
at two stages. In the early stages of infection bacteria may interact with locally 
synthesised complement proteins within the urinary space. The kidney is an important 
extra-hepatic source of complement synthesis and can contribute up to 12% of the 
circulating pool of C3 (Tang et al., 1999b). The predominant site of C3 expression is 
the renal tubule, which shows both constitutive and cytokine-dependent synthesis of 
most complement proteins (Brooimans et al., 1991; Seelen et al., 1993). Human 
tubular epithelial cells secrete C3 both from the basolateral and apical surfaces and 
therefore C3 could be secreted into urine (Tang et al., 1999a). Increased levels of C3, 
both intact and activated forms, are found in the urine of patients with acute infection 
(Li et al., 2006; Negi et al., 2000). However, under these circumstances the 
concentration of complement proteins would be relatively low. The second interaction 
is within the interstitial compartment after bacterial invasion of the host epithelium. In 
this circumstance, the complement concentration may be equivalent to that in serum.
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To mimic these two conditions, uropathogenic E. coli were incubated in different 
concentrations of complement proteins and the contribution of each complement 
activation pathway to bacterial opsonisation assessed.  At higher protein
concentrations (????? serum, reflecting the concentration in tissues) the alternative 
pathway was responsible for 90% of the C3 deposited on the bacterial surface. 
However, maximal activation of the alternative pathway still required the classical 
pathway. In its absence opsonisation was slower and therefore presumably less 
efficient. At lower complement protein concentrations (less than 5% serum, more 
representative of concentrations present in urine), E. coli activated complement 
mainly through the classical pathway. Although it has been reported that MBL can 
bind to the O-antigen region of LPS, a structural component of the outer membrane of 
Gram-negative bacteria (Selander et al., 2006; Zhao et al., 2002), the MBL pathway 
had little role in the opsonisation of uropathogenic E. coli. This was confirmed by 
experiments showing that either inhibition of MBL binding or use of MBL deficient 
serum had little effect on C4 deposition on bacteria. Our results indicate the relative 
contribution of each pathway is dependent on complement protein concentration. The 
initiation of complement activation depends mainly on the classical pathway and the 
major role of the alternative pathway is amplification of C3 deposition. 
Similar studies have been performed on other bacterial pathogens. Cunnion et al 
assessed C3 deposition on Staphylococcus aureus in different serum concentrations. 
Their results suggested the classical and alternative pathways both contribute to C3 
deposition, the classical pathway predominating at a lower serum concentration (2%) 
and the alternative pathway at a higher serum concentration (20%) (Cunnion et al., 
2001). Several studies have demonstrated a key role for the classical pathway in 
initiating complement opsonisation of Streptococcus pneumoniae. The major role of 
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the alternative pathway being amplification of complement activation leading to 
greater C3 deposition on the bacteria (Brown et al., 2002; Xu et al., 2001). 
In our previous report, we demonstrated that C3 from infected urine could bind to E.
coli. In the present study we have shown that, as would be predicted from in vitro 
studies, this binding is due mainly to classical pathway activation, as calcium 
chelation reduced C3 binding to E. coli. Secondly, we demonstrated that early 
components of the classical pathway components (C1q, C4 and C2) are present in the 
infected urine and their concentrations are high enough to allow activation to occur. 
Thirdly, we determined that local synthesis contributes to the increased concentration 
of complement proteins in urine.  Finally, we found that the classical pathway can be 
activated via several routes. Antibodies against uropathogenic bacteria are present in 
the infected urine and could initiate complement activation. Other possible 
mechanisms by which bacteria could activate the classical pathway is through either 
direct binding of C1q to bacteria or by interaction with the acute-phase protein, CRP,
bound to bacteria. 
The consequence of bacterial opsonisation within the urinary space is still unclear. It 
could enhance phagocytosis by infiltrating neutrophils leading to the elimination of 
infection. However, bacteria continue to develop strategies to avoid, or even subvert, 
the host immune response. It has been demonstrated that C3 opsonisation markedly 
increases the ability of uropathogenic E. coli to internalise into human uroepithelial 
cells, perhaps as a means of evading neutrophil-mediated phagocytosis (Li et al., 
2006). In addition, internalised bacteria may either proliferate leading to host cell 
death or remain quiescent inside vacuoles, reactivating at a later stage to cause 
recurrent infection (Schilling et al., 2002). In the balance between microbe and host, 
18
the susceptibility of an individual to UTI may depend on the levels of urine C3 and /or 
cell surface complement receptors. 
In summary, we have demonstrated that the complement classical pathway is 
important for efficient opsonisation of pathogenic E. coli and hypothesise that 
complement opsonisation plays a critical role during the first encounter of the 
pathogen with the host epithelium. 
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Figure Legends 
Figure 1. The contribution of the alternative pathway to C3 opsonisation
A) Flow cytometry data for C3 deposition on E. coli J96 after incubation in different 
serum concentrations for 30 minutes with all complement pathways active (black 
line), with only the alternative pathway active (interrupted line) and in the absence of 
complement activation (grey line). Each data point represents the mean of 4 assays 
(+/- SEM). (B and C) Representative examples of flow cytometry data for bacteria 
incubated with different sera concentrations (B 2.5%, C 10%). All pathways active 
(black line); the alternative pathway only active (interrupted line); no complement 
activation (grey line). (D). The E. coli pyelonephritis isolate GR-12 was incubated in 
different serum concentrations. Each data point represents the mean of 4 assays (+/-
SEM). Lines are the same as panel A.
Figure 2. Time dependent C3 deposition on E. coli
C3 deposition on E. coli J96 over time in 2% (A) and 10% serum (B) with all 
complement pathways active, the alternative pathway only or no activation. When all 
pathways were active maximal opsonisation was achieved by 5 minutes. In 2% serum 
the alternative pathway alone was unable to opsonise bacteria. In 10% serum 
alternative pathway mediated opsonisation occurred but more slowly. Each data point 
represents the mean of four independent experiments. Error bars represent SEM. 
Figure 3. Dissection of the contribution of the classical and MBL pathways 
Representative flow cytometry data for C4 staining on E. coli J96 incubated at 37oc
for 20 minutes with; (A) C1q depleted serum; (B) normal human serum diluted in 
25
buffer containing 1M NaCl; (C) MBL depleted serum; (D) normal serum diluted in 
buffer containing 100mM mannose. The black line represents the C4 deposition in 
standard serum conditions. The interrupted line represents either the complement 
depleted/deficient serum or normal serum diluted in pathway inhibition buffers as 
stated in the title of each panel. The grey line represents an assay in which the primary 
antibody was omitted.
Figure 4. E. coli J96 fixes C3 protein in infected urine
C3 fragments deposited on J96 after incubation with the urine (concentrated 10 fold)
of a patient with UTI were detected by C3 Western blot analysis. Purified C3b 
(0.2µg) was ran in parallel (lane 1). E. coli J96 were incubated with urine alone (lane 
2); urine in the presence of Mg-EGTA (lane 3); in the presence of EDTA (lane 4). 
The presence of C3b is indicated by 105 kDa (a’????????????????????????????????????
???????????????????????????????????1??????????????????????2 chain) bands.
Figure 5. Identification of C1q, C2 and C4 in urine of patients with UTI
The presence of classical pathway components C1q, C2 and C4 in the urine of a 
patient with UTI. (A) Three sub-units of C1q (A 29kDa, B 26kDa, and C 22 kDa) 
were all detected in infected urine samples (1:5 dilution). (B) The single chain of C2 
was present in infected urine (1:10 dilution). (C) Intact C4 (???? and ? chains, 95,75
and 33 kDa respectively) were present in infected urine (1:5 dilution). Human serum 
(1:200 dilution) was used as a positive control.
Figure 6. Measurement of C1q concentrations in urine
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Urine C1q concentration was determined by ELISA. The urine C1q concentration was 
corrected for urinary creatinine (A) or urinary albumin (B). C1q in urine from acute 
UTI patients (n=20) were compared with the level in control, non-infected, urine 
samples (n=6).
Figure 7. Detection IgM, IgG and IgA binding to E. coli
The ability of immunoglobulins to bind to uropathogenic E. coli was determined by 
FACS staining. IgG, IgM and IgA binding was assessed after incubating E. coli with 
5% normal serum (left panel). The solid line represents the Ig deposition. The 
interrupted line represents bacteria stained with detection antibody only as control. 
The right panel shows immunoglobulin binding after incubation with infected urine 
(solid black line) or control urine (interrupted black line). The interrupted gray line 
represents bacteria stained with detection antibody only as control. The examples are 
representative of at least 3 independent experiments.
Figure 8. Detection the direct binding of C1q and CRP to E. coli
C1q and CRP binding to E. coli J96 after incubation??????????????????????????????A)
or CRP (160ng/ml and 1600ng/ml) (B) for 30 minutes. The solid line represents the 
C1q or CRP deposition. The interrupted line represents an assay in which the primary 
antibody was omitted. 
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Figure 4. E.coli actives the classical pathway in infected urine
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Figure 7. Detection of human Ig on opsonised E.coli
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Figure 8. C1q and CRP could bind directly to E. coli
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